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Abstract 
Introduction: In inflammatory bowel disease 
(IBD), commonly used biomarkers employed for non-
invasive monitoring of disease activity are the C-
reactive Protein (CRP) and Erythrocyte 
Sedimentation Rate (ESR). Ulcerative colitis (UC) 
has a modest to absent CRP response despite active 
inflammation. Iron deficiency anaemia (IDA) is often 
a marker of active disease in IBD.   
Methods: CRP, ESR, and Haemoglobin level taken 
within 7 days of a colonoscopy were analysed and 
compared with histopathological findings from 
colonic and ileal biopsies. 
Results:  Colonic biopsies from 95 colonoscopies 
in UC patients; and colonic and ileal biopsies from 98 
colonoscopies in CD patients were analyzed. The 
Positive Predictive Values and Negative Predictive 
Values relating to ESR, CRP and iron deficiency anaemia 
in the two groups of patients were calculated.   
Conclusion: UC has a similar CRP response to CD 
in active inflammation. Commonly used biomarkers 
have poor sensitivities in demonstrating active 
mucosal disease. IDA has little value when used as a 
marker of disease activity on its own but may be used 
as an adjunct to ESR and CRP. Faecal biomarkers and 
novel antibodies may help to increase the sensitivity 
and specificity in non-invasive monitoring of IBD.  
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Introduction 
In inflammatory bowel disease (IBD), biomarkers 
are desirable tools that are often used to gain objective 
measurements of disease activity and severity, as well 
as to quantify responses to therapy. The ideal 
biomarker for IBD does not exist and more than one 
biomarker is usually employed. Biological markers 
that have found use in assessing IBD include acute-
phase proteins, faecal markers, antibodies and novel 
genetic determinants.   
The acute-phase proteins most used in clinical 
practice are the C-reactive protein (CRP) and the 
erythrocyte sedimentation rate (ESR). They are 
potential laboratory surrogate markers for disease 
activity and are associated with endoscopic 
inflammation and severely active histologic 
inflammation.
1
 CRP and ESR are also the two main 
biomarkers used in gastroenterology out-patients 
clinics to measure disease activity in patients with 
ulcerative colitis and Crohn’s disease. But how 
accurately do these tests measure IBD activity? 
CRP is the most studied acute-phase protein and it 
has been shown to be an objective marker of 
inflammation. Solem et al showed that CRP elevation 
in IBD patients is associated with clinical disease 
activity, endoscopic inflammation, severely active 
histologic inflammation (only in Crohn’s disease 
patients), and several other biomarkers of 
inflammation, but does not correlate with radiographic 
activity.
2 
 The authors observed that CRP had 54% 
sensitivity and 75% specificity for Crohn’s disease in 
105 patients. In a study of 43 patients with ulcerative 
colitis, 19 of 37 (51%) patients with active disease 
based on colonoscopic analysis had increased levels of 
CRP whereas 0 of 6 patients without endoscopic 
evidence of disease activity had increased levels of 
CRP.
 2 
The production of CRP occurs mostly in the liver 
by the hepatocytes as part of the acute phase response. 
Hepatocytes synthesize CRP extremely rapidly, with a 
500 to 1,000 fold higher increase than under basal 
circumstances occurring within 24 – 48 hours of the 
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onset of inflammation. The reduction in plasma CRP 
concentration as the acute phase response subsides may be 
similarly rapid. The biological half life of the circulating 
protein itself is short (19 hours) thus making CRP a 
valuable marker to detect and follow up disease activity in 
Crohn’s disease (CD). In contrast, ulcerative colitis is 
believed to have only a modest to absent CRP response 
despite active inflammation and the reason for this is 
unknown.
3
  
Erythrocyte Sedimentation Rate (ESR) analysis is 
commonly performed in IBD. ESR measures the distance 
that erythrocytes have fallen after one hour in a vertical 
column of anticoagulated blood under the influence of 
gravity.
4
 ESR varies with plasma protein concentration and 
the haematocrit values and in IBD provides a crude and 
rapid assessment of the plasma protein alterations of the 
acute phase response. ESR tends to be influenced by 
multiple factors including increasing age, gender, 
pregnancy, anaemia, temperature, handling of the ESR 
tube, infection, malignancy, red blood cell abnormalities 
and technical factors.
5
 Repeatedly, ESR determinations 
have been shown to be satisfactory monitors of acute-
phase response to disease after the first 24 hours, while 
CRP tends to be a better indicator in the first 24 hours.
6 
 
Compared with CRP, ESR will peak much less rapidly and 
may also take several days to decrease, even if the clinical 
condition of the patient or the inflammation is 
ameliorated.
7 
Iron deficiency anaemia (IDA) is also another marker 
of mucosal inflammation, though the time required for iron 
deficiency to develop is even longer and it usually takes a 
number of weeks after the onset of inflammation for the 
Mean Corpusclar Volume (MCV) and the Haemoglobin to 
drop. Iron deficiency anaemia occurs when the 
Haemoglobin is less than 14 g/dl in men and less than 12 g 
/ dl in women in the presence of reduced iron stores (low 
serum ferritin <30 pg/L, serum iron < 10 pmol/L, 
transferring saturation <20% or total iron binding capacity 
> 45 pmol/L).  Since ferritin is an inflammatory marker 
and may be raised in active inflammation, checking serum 
iron, transferrin saturation and total iron binding capacity 
may be necessary for the diagnosis of iron deficiency.  
While CRP is the fastest rising acute phase protein with 
ESR rising after the first 24 hours, iron deficiency 
develops over a number of weeks and therefore might 
represent a marker of longstanding disease activity. 
 
Aim 
The aim of this study was to assess the reliability of 
ESR and CRP in detecting active mucosal inflammation in 
inflammatory bowel disease. The reliability of IDA in IBD 
as a marker of recent ongoing inflammation was also 
analysed. We also studied the relationship between disease 
location and behaviour in Crohn’s disease with the 
sensitivity, specificity and predictive values of CRP.   
 
 
Methods 
Patients with endoscopically and histologically 
confirmed ulcerative colitis and Crohn’s disease were 
studied. Through the iSOFT
®
 laboratory results 
database system, all colonic biopsies taken at Mater 
dei Hospital between May 2010 and May 2011 from 
these patients were analysed retrospectively. Using the 
same software system, any CRP, ESR, Haemoglobin 
level, serum ferritin and Mean Corpuscular Volume 
(MCV) taken within 7 days of the colonic and terminal 
ileal biopsies were collected. The data was stored in a 
spreadsheet (Microsoft Office Excel 2007
®
) and the 
biochemical data was compared with the 
histopathology reports. Any histological evidence of 
inflammation (including mild inflammation) was taken 
as evidence of disease activity. The sensitivity, 
specificity, positive and negative predictive values of 
the CRP, ESR, IDA and both inflammatory markers 
together were analysed. Sensitivity, specificity, 
positive and negative predictive values of the CRP in 
different Crohn’s disease phenotypes (depending on 
Crohn’s disease location and type, as classified by the 
Montreal classification) was also analysed.  The 
Montreal classification describes Crohn’s disease 
according to the following criteria: 
 Age at Diagnosis: 
o A1: Diagnosed < 17 years 
o A2: Diagnosed at 17 – 40 
years 
o A3: Diagnosed > 40 years 
 Disease Location: 
o L1: Ileal disease 
o L2: Colonic disease 
o L3: Ileo-colonic disease 
 Disease Type: 
o B1: non-stricturing, non-
pentrating disease 
o B2: structuring disease 
o B3: penetrating disease 
 
Results 
Colonic biopsies from 95 colonoscopies done in 71 
different patients with known ulcerative colitis were 
analysed. Table 1 describes the sensitivities, 
specificities, positive and negative predictive values of 
CRP, ESR and IDA in patients with ulcerative colitis. 
In patients with histological and endoscopic evidence 
of left sided active colitis, the sensitivity of CRP was 
50% (true positive: 11, false negative: 11 cases). In 
patients with active proctitis, the sensitivity was 33.3% 
(true positive: 3, false negative: 6) while in patients 
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with pancolitis, the sensitivity was 42.3% (true positive; 11, 
false negative: 15 cases).  
 
 
Marker Sensitivity Specificity PPV NPV 
CRP 44.6% 94.1% 92.6% 50.7% 
ESR 64.7% 89.3% 91.7% 58.1% 
IDA 24.6% 100% 100% 39.5% 
ESR & 
CRP 
75.9% 90% 93.2% 67.5% 
ESR, 
CRP & 
IDA 
70% 85.3% 89.3% 61.7% 
Table 1: Sensitivities, specificities and predictive values of 
inflammatory markers and iron deficiency anaemia in ulcerative 
colitis patients. (PPV – Positive Predictive Value, NPV – 
Negative Predictive Value) 
 
 
Marker Sensitivity Specificity PPV NPV 
CRP 54.5% 71.0% 80% 42.3% 
ESR 55.4% 89.7% 91.2% 50.9% 
IDA 44.1% 87.5% 93.8% 42.4% 
ESR & 
CRP 
70.9% 70.0% 83.0% 53.8% 
ESR, 
CRP & 
IDA 
74.6% 68.7% 83.3% 56.4% 
Table 2: Sensitivities, specificities and predictive values of 
inflammatory markers and iron deficiency anaemia in Crohn’s 
disease patients. (PPV  – Positive Predictive Value, NPV – 
Negative Predictive Value) 
 
 
CRP L1 L2 L3 
Sensitivity 80% 62.9% 46.8% 
Specificity 50% 90.9% 62.5% 
PPV 57.1% 94.4% 83.3% 
NPV 75% 50% 22.7% 
Table 3: Crohn’s Disease Location and CRP.  (L1 – ileal 
disease, L2 – colonic disease, L3 – ileocolonic disease, PPV – 
Positive Predictive Value, NPV – Negative Predictive Value) 
 
Colonic and terminal ileal biopsies from 98 
colonoscopies in 62 different patients with known Crohn’s 
disease were analysed. Table 2 describes the sensitivities, 
specificities positive and negative predictive values of 
CRP, ESR and IDA in Crohn’s disease patients. Table 3 
describes the sensitivities, specificities and predictive 
values of CRP with disease location as classified by the 
Montreal Classification while Table 4 shows the 
sensitivities, specificities and predictive values of CRP in 
predicting Crohn’s disease behaviour as classified by the 
same classification. CRP in patients on biological therapy 
for Crohn’s disease showed a sensitivity of 55%, a 
specificity of 54.5%, a positive predictive value of 81.5% 
and a negative predictive value of 25% (True Positive 
– 22, False Positive – 5, True Negative – 6, False 
Negative – 18). 
 
 
CRP B1 B2 B3 
Sensitivity 55.5% 66.6% 0% 
Specificity 100% 50% 50% 
PPV 100% 70.6% 0% 
NPV 47.8% 45.5% 50% 
Table 4: Crohn’s Disease behaviour and CRP.  (B1 – non-
stricturing non-penetrating disease, B2 – stricturing disease, 
B3 – penetrating disease, PPV – Positive Predictive Value, 
NPV – Negative Predictive Value).   
 
Discussion 
CRP exhibits similar sensitivities, specificities and 
predictive values in UC and CD. We have shown that 
UC has a similar CRP response to CD in active 
inflammation. However, both the CRP and the ESR 
tend to have a poor sensitivity in identifying disease 
activity. Sensitivity tends to improve if both 
inflammatory markers are analysed together. 
Specificity also tends to be unacceptably low since a 
false positive result means that patients will need to 
undergo unnecessary invasive endoscopies or an 
increase in their treatment.  
Disease location and behaviour in Crohn’s disease 
may also affect the sensitivity and specificity of the C-
Reactive Protein, with ileal and stricturing disease 
having the best sensitivities (see Tables 3 and 4). 
However, the sensitivities and specificities of different 
disease locations and behaviours still remain 
unacceptably low. 
Limitations in this study may affect the value of the 
statistical measures described. One of the limitations is 
that blood tests taken up to one week before the 
endoscopy were included, thus potentially affecting 
sensitivity since the CRP with its short half-life might 
have improved in the interim. In fact, when the ESR 
and CRP were analysed together there was an 
improved sensitivity in detecting disease activity. 
Another limitation is that even with serial colonic 
biopsies, areas of inflammation may be missed during 
endoscopic examination of the colon. This is even 
more evident in Crohn’s disease affecting the small 
bowel where histological evidence of inflammation is 
usually very difficult to obtain. A normal colonoscopy 
does not exclude the presence of ongoing 
inflammation in the small bowel. In fact, specificity of 
the inflammatory markers in Crohn’s disease was 
lower than in ulcerative colitis. 
Mucosal inflammation may lead to a drop in 
haemoglobin (secondary to anaemia of chronic 
disease) or a rise in serum ferritin.  While iron 
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deficiency is the commonest cause of anaemia in IBD, 
serum iron, transferrin saturation and total iron binding 
capacity levels may be needed to confirm the presence of 
iron deficiency during active inflammation. 
Notwithstanding these limitations, the poor sensitivity 
and specificity of ESR and CRP is reflected in our every 
day practice. Patients frequently present with symptoms of 
ongoing active disease, like diarrhoea, bleeding per rectum, 
weight loss, and anaemia but with normal inflammatory 
markers.   
Iron deficiency anaemia has good specificity but very 
poor sensitivity in both Crohn’s disease and ulcerative 
colitis. While IDA may be used as an adjunct to ESR and 
CRP or other biomarkers, it has little value when used as a 
marker of disease activity on its own.   
Therefore better biomarkers are needed for the non-
invasive monitoring of ulcerative colitis and Crohn’s 
disease. Fecal calprotectin and lactoferrin concentrations 
correlate better with colonic than ileal disease activity 
although extent of colonic disease does not appear to be 
important.
9-11
 The sensitivities of tests for calprotectin to 
detect any mucosal disease range from 70% to 100% with 
a specificity range of 44% to 100%, depending on the cut 
off point used.
12-17
 Sensitivities and specificities of tests for 
lactoferrin are similar.   
In general, the correlation between CRP and 
endoscopic activity is lower than that observed between 
feacal markers and activity. Similarly, sensitivity and 
specificity for active mucosal inflammation is likely to be 
lower for CRP compared with fecal markers. In the study 
by Solem et al, 86% of patients (n=43) with any clinical 
symptoms of Crohn’s disease and with increased levels of 
CRP had evidence of mucosal inflammation based on 
colonoscopic findings.
2
 Some patients have persistently 
normal levels of CRP despite active disease.
18
 For these 
patients, feacal biomarkers should be used preferentially to 
differentiate quiescent from active disease. Feacal 
calprotectin and lactoferrin also tend to have higher 
sensitivity and specificity in predicting mucosal healing.
19 
Siponnen et al found a 66-71% sensitivity and 83-92% 
specificity with fecal lactoferrin, 70-91% sensitivity and 
44-92% specificity with calprotectin and 48% sensitivity 
and 91% specificity with CRP in Crohn’s disease 
patients.
16
 Schoepfer et al showed an 89% sensitivity and 
58% specificity with fecal calprotectin versus 68% 
sensitivity and 58% specificity with CRP.
14
    
As opposed to regular CRP, high sensitivity CRP 
(hsCRP) assays may allow detection of low grade 
inflammation in patients with IBD although the routine use 
of this test is not yet readily available.
20
 
In IBD, biomarkers may play a useful role in 
distinguishing between Crohn’s disease and ulcerative 
colitis. Antibodies against luminal antigens like 
antineutrophil cytoplasmic autoantibodies (ANCA), anti-
Saccharomyces cerevisae antibodies (ASCA), OmpC 12 
and CBir1 Flagellin are specifically associated with 
Crohn’s disease. The contribution of serologic markers, 
specifically the anti-glycan antibodies, to IBD 
diagnosis may be in differentiating IBD from other 
gastrointestinal diseases, in differentiating Crohn’s 
disease from ulcerative colitis, in better classifying 
indeterminate colitis and in decision-making prior to 
proctocolectomy in UC patients. The anti-glycan 
antibodies are specifically important in ASCA-
negative Crohn’s disease patients.21     
 
Conclusion 
In inflammatory bowel disease biomarkers may 
help in assessing disease activity and mucosal healing. 
Ulcerative colitis has a similar CRP response to 
Crohn’s disease in active inflammation. IDA has little 
value when used as a marker of disease activity on its 
own but may be used as an adjunct to ESR and CRP or 
other biomarkers. No single test provides 100% 
sensitivity and specificity. Combinations of fecal and 
serological markers may be used to identify patients 
who should undergo earlier invasive testing or who 
require a step-up in treatment. Biomarkers such as 
calprotectin and lactoferrin provide better sensitivities 
and specificities and can be used to assess mucosal 
healing without the need for invasive testing or 
radiation. Antibodies against luminal antigens may 
prove useful in the future but are still too expensive for 
every day practice and require further research before 
they can be recommended.  
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